Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.57 |
| ▸ | CDC25B | P30305 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | BLM | P54132 | 3/20 | 0.52 |
| ▸ | S100A4 | P26447 | 3/20 | 0.52 |
| ▸ | APAF1 | O14727 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30004167 | 1.00 | FGFR1 (0.57) | FGFR1FGFR2FGFR4FGFR3CDC25B | |
| SCHEMBL14307224 | 0.89 | FGFR1 (0.49) | FGFR1FGFR2FGFR4FGFR3CDC25B | |
| SCHEMBL571496 | 0.86 | MAPT (0.56) | FGFR1FGFR2FGFR4FGFR3CDC25B | |
| SCHEMBL21814476 | 0.84 | FGFR1 (0.53) | FGFR1FGFR2FGFR4FGFR3CDC25B | |
| SCHEMBL28303007 | 0.84 | FGFR1 (0.49) | FGFR1FGFR2FGFR4FGFR3CDC25B | |
| SCHEMBL8781044 | 0.84 | APAF1 (0.60) | FGFR1FGFR2FGFR4FGFR3CDC25B | |
| SCHEMBL9627696 | 0.84 | IDO1 (0.60) | FGFR1FGFR2FGFR4FGFR3CDC25B | |
| SCHEMBL9628254 | 0.83 | MAPT (0.65) | FGFR1FGFR2FGFR4FGFR3CDC25B | |
| SCHEMBL9627536 | 0.83 | CDC25B (0.53) | FGFR1FGFR2FGFR4FGFR3CDC25B | |
| SCHEMBL14307223 | 0.80 | CDC25B (0.50) | FGFR1FGFR2FGFR4FGFR3CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11613509-B2 | Radical polymerization control agent and radical polymerization control method | KAWASAKI KASEI CHEMICALS LTD. (JP) | 2023-03-28 | — | — | US | disclosed |
| CN-110891980-B | Radical polymerization control agent and radical polymerization control method | 川崎化成工业株式会社 | 2022-09-30 | — | — | CN | disclosed |
| US-20210122692-A1 | RADICAL POLYMERIZATION CONTROL AGENT AND RADICAL POLYMERIZATION CONTROL METHOD | KAWASAKI KASEI CHEMICALS LTD. (JP) | 2021-04-29 | — | — | US | disclosed |
| CN-110891980-A | Radical polymerization control agent and radical polymerization control method | 川崎化成工业株式会社 | 2020-03-17 | — | — | CN | disclosed |
| WO-2006107827-A1 | SKIN BONDING PROCESS | CREIGHTON UNIVERSITY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11613509-B2 | Radical polymerization control agent and radical polymerization control method | PPOX, NOX4, CROCC | FGFR1 4096/4885FGFR2 4418/4885FGFR4 3556/4885 |
| US-20210122692-A1 | RADICAL POLYMERIZATION CONTROL AGENT AND RADICAL POLYMERIZATION CONTROL METHOD | PPOX, NOX4, CROCC | FGFR1 4096/4885FGFR2 4418/4885FGFR4 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.